Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
JerseyIPO:
01 October 2015Website:
http://www.novocure.comNext earnings report:
21 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:24:11 GMTDividend
Analysts recommendations
Institutional Ownership
NVCR Latest News
NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar - H.C. Wainwright Jessica Fye - JPMorgan Operator Good day, and thank you for standing by.
NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.
NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. “Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a.
The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.
The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.
NovoCure (NVCR) reported a quarterly loss of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.43. This is an improvement from the loss of $0.50 per share reported a year ago.
NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What type of business is NovoCure Limited?
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
What sector is NovoCure Limited in?
NovoCure Limited is in the Healthcare sector
What industry is NovoCure Limited in?
NovoCure Limited is in the Medical Devices industry
What country is NovoCure Limited from?
NovoCure Limited is headquartered in Jersey
When did NovoCure Limited go public?
NovoCure Limited initial public offering (IPO) was on 01 October 2015
What is NovoCure Limited website?
https://www.novocure.com
Is NovoCure Limited in the S&P 500?
No, NovoCure Limited is not included in the S&P 500 index
Is NovoCure Limited in the NASDAQ 100?
No, NovoCure Limited is not included in the NASDAQ 100 index
Is NovoCure Limited in the Dow Jones?
No, NovoCure Limited is not included in the Dow Jones index
When was NovoCure Limited the previous earnings report?
No data
When does NovoCure Limited earnings report?
The next expected earnings date for NovoCure Limited is 21 February 2025